These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19728346)

  • 1. N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands.
    Rivara S; Vacondio F; Fioni A; Silva C; Carmi C; Mor M; Lucini V; Pannacci M; Caronno A; Scaglione F; Gobbi G; Spadoni G; Bedini A; Orlando P; Lucarini S; Tarzia G
    ChemMedChem; 2009 Oct; 4(10):1746-55. PubMed ID: 19728346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands.
    Rivara S; Lodola A; Mor M; Bedini A; Spadoni G; Lucini V; Pannacci M; Fraschini F; Scaglione F; Sanchez RO; Gobbi G; Tarzia G
    J Med Chem; 2007 Dec; 50(26):6618-26. PubMed ID: 18052314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands.
    Bedini A; Spadoni G; Gatti G; Lucarini S; Tarzia G; Rivara S; Lorenzi S; Lodola A; Mor M; Lucini V; Pannacci M; Scaglione F
    J Med Chem; 2006 Dec; 49(25):7393-403. PubMed ID: 17149869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
    Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
    J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives as novel melatonin receptor ligands.
    Li G; Zhou H; Jiang Y; Keim H; Topiol SW; Poda SB; Ren Y; Chandrasena G; Doller D
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1236-42. PubMed ID: 21237644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability.
    Ferlenghi F; Mari M; Gobbi G; Elisi GM; Mor M; Rivara S; Vacondio F; Bartolucci S; Bedini A; Fanini F; Spadoni G
    ChemMedChem; 2021 Oct; 16(19):3071-3082. PubMed ID: 34213063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-methoxy-1-methyltryptamines.
    Tsotinis A; Vlachou M; Papahatjis DP; Calogeropoulou T; Nikas SP; Garratt PJ; Piccio V; Vonhoff S; Davidson K; Teh MT; Sugden D
    J Med Chem; 2006 Jun; 49(12):3509-19. PubMed ID: 16759094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-[2-[2-(4-Phenylbutyl)benzofuran-4-yl]cyclopropylmethyl]acetamide: an orally bioavailable melatonin receptor agonist.
    Sun LQ; Takaki K; Chen J; Iben L; Knipe JO; Pajor L; Mahle CD; Ryan E; Xu C
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5157-60. PubMed ID: 15380218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors.
    Audinot V; Bonnaud A; Grandcolas L; Rodriguez M; Nagel N; Galizzi JP; Balik A; Messager S; Hazlerigg DG; Barrett P; Delagrange P; Boutin JA
    Biochem Pharmacol; 2008 May; 75(10):2007-19. PubMed ID: 18384758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands.
    Poissonnier-Durieux S; Ettaoussi M; Pérès B; Boutin JA; Audinot V; Bennejean C; Delagrange P; Caignard DH; Renard P; Berthelot P; Lesieur D; Yous S
    Bioorg Med Chem; 2008 Sep; 16(18):8339-48. PubMed ID: 18778943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands.
    Markl C; Attia MI; Julius J; Sethi S; Witt-Enderby PA; Zlotos DP
    Bioorg Med Chem; 2009 Jul; 17(13):4583-94. PubMed ID: 19473848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT₂-selective agonists.
    Koike T; Hoashi Y; Takai T; Nakayama M; Yukuhiro N; Ishikawa T; Hirai K; Uchikawa O
    J Med Chem; 2011 May; 54(9):3436-44. PubMed ID: 21473625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards the development of mixed MT(1)-agonist/MT(2)-antagonist melatonin receptor ligands.
    Spadoni G; Bedini A; Guidi T; Tarzia G; Lucini V; Pannacci M; Fraschini F
    ChemMedChem; 2006 Oct; 1(10):1099-105. PubMed ID: 16955531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antinociceptive properties of selective MT(2) melatonin receptor partial agonists.
    López-Canul M; Comai S; Domínguez-López S; Granados-Soto V; Gobbi G
    Eur J Pharmacol; 2015 Oct; 764():424-432. PubMed ID: 26162699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: comparison with melatonin and diazepam.
    Ochoa-Sanchez R; Rainer Q; Comai S; Spadoni G; Bedini A; Rivara S; Fraschini F; Mor M; Tarzia G; Gobbi G
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):318-25. PubMed ID: 22789661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in melatonin receptor ligands.
    Zlotos DP
    Arch Pharm (Weinheim); 2005 Jun; 338(5-6):229-47. PubMed ID: 15952241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and pharmacological effects of structurally simple ligands for MT(1) and MT(2) melatonin receptors.
    Carocci A; Catalano A; Lovece A; Lentini G; Duranti A; Lucini V; Pannacci M; Scaglione F; Franchini C
    Bioorg Med Chem; 2010 Sep; 18(17):6496-511. PubMed ID: 20674373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of substituted N-[3-(3-methoxylphenyl)propyl] amides as MT(2)-selective melatonin agonists: improving metabolic stability.
    Hu Y; Zhu J; Chan KH; Wong YH
    Bioorg Med Chem; 2013 Jan; 21(2):547-52. PubMed ID: 23228808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular cloning and pharmacological characterization of monkey MT1 and MT2 melatonin receptors showing high affinity for the agonist ramelteon.
    Nishiyama K; Shintani Y; Hirai K; Yoshikubo S
    J Pharmacol Exp Ther; 2009 Sep; 330(3):855-63. PubMed ID: 19556449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides.
    Rivara S; Pala D; Lodola A; Mor M; Lucini V; Dugnani S; Scaglione F; Bedini A; Lucarini S; Tarzia G; Spadoni G
    ChemMedChem; 2012 Nov; 7(11):1954-64. PubMed ID: 22927210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.